Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/IIa study to assess safety, tolerability, pharmacokinetic, pharmacodynamic effects and exploratory efficacy of two doses of AGMG0201 in patients with essential hypertension

Next Previous
Trial Profile

A phase I/IIa study to assess safety, tolerability, pharmacokinetic, pharmacodynamic effects and exploratory efficacy of two doses of AGMG0201 in patients with essential hypertension

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AGMG-0201 (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Sponsors AnGes

Most Recent Events

  • 10 Dec 2021 Status changed from recruiting to completed.
  • 12 Apr 2018 According to an AnGes MG media release, the first patient was treated with DNA vaccine for hypertension on April 12, 2018 in this Australian phase I / II clinical study.
  • 12 Apr 2018 Status changed from not yet recruiting to recruiting, according to an AnGes MG media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top